A roundup of exits, including IPOs and acquisitions, across the tech transfer ecosystem.

Affinia Therapeutics, a US-based gene therapy developer based on research at Harvard University, has filed to raise up to $100m in an initial public offering on the Nasdaq Global Market that would represent an exit for chemical producer Lonza, internet and technology group Alphabet and care provider Mass General Brigham. The company had raised $170m…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.